{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:03:20Z","timestamp":1784822600511,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00935-x","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:53:24Z","timestamp":1777366404000},"page":"1593-1611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Collaborative Approach to Creating Knowledge-Building Resources for the Early-Stage Parkinson\u2019s Disease Community"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6224-7573","authenticated-orcid":false,"given":"Soania","family":"Mathur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3924-0269","authenticated-orcid":false,"given":"Becky","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7926-1543","authenticated-orcid":false,"given":"Angels","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Trenam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"935_CR1","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C. Parkinson\u2019s disease. Lancet. 2021;397:2284\u2013303.","journal-title":"Lancet"},{"key":"935_CR2","first-page":"504","volume":"40","author":"G DeMaagd","year":"2015","unstructured":"DeMaagd G, Philip A. Parkinson\u2019s disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. P T. 2015;40:504\u201332.","journal-title":"P T"},{"key":"935_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/biomedicines10020371","volume":"10","author":"NA Gouda","year":"2022","unstructured":"Gouda NA, Elkamhawy A, Cho J. Emerging therapeutic strategies for Parkinson\u2019s disease and future prospects: a 2021 update. Biomedicines. 2022;10:371.","journal-title":"Biomedicines"},{"key":"935_CR4","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.parkreldis.2015.09.004","volume":"22","author":"RF Pfeiffer","year":"2016","unstructured":"Pfeiffer RF. Non-motor symptoms in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2016;22:S119\u201322.","journal-title":"Parkinsonism Relat Disord"},{"key":"935_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3233\/JPD-239901","volume":"13","author":"K McFarthing","year":"2023","unstructured":"McFarthing K, Buff S, Raloff G, et al. Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2023 update. J Parkinsons Dis. 2023;13:427\u201339.","journal-title":"J Parkinsons Dis"},{"key":"935_CR6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"J Jankovic","year":"2020","unstructured":"Jankovic J, Tan EK. Parkinson\u2019s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91:795\u2013808.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"935_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40035-022-00286-1","volume":"11","author":"P Mahlknecht","year":"2022","unstructured":"Mahlknecht P, Marini K, Werkmann M, Poewe W, Seppi K. Prodromal Parkinson\u2019s disease: hype or hope for disease-modification trials? Transl Neurodegener. 2022;11:11.","journal-title":"Transl Neurodegener"},{"key":"935_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2217\/nmt-2021-0058","volume":"13","author":"M Amin","year":"2023","unstructured":"Amin M, Hersh CM. Updates and advances in multiple sclerosis neurotherapeutics. Neurodegener Dis Manag. 2023;13:47\u201370.","journal-title":"Neurodegener Dis Manag"},{"key":"935_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","volume":"83","author":"J Cummings","year":"2023","unstructured":"Cummings J. Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer\u2019s disease therapeutics. Drugs. 2023;83:569\u201376.","journal-title":"Drugs"},{"key":"935_CR10","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41582-024-01023-0","volume":"20","author":"LV Kalia","year":"2024","unstructured":"Kalia LV, Asis A, Arbour N, et al. Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis. Nat Rev Neurol. 2024;20:724\u201337.","journal-title":"Nat Rev Neurol"},{"key":"935_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.14802\/jmd.25008","volume":"18","author":"SH Jeong","year":"2025","unstructured":"Jeong SH, Lee PH. Drug repositioning and repurposing for disease-modifying effects in Parkinson\u2019s disease. J Mov Disord. 2025;18:113\u201326.","journal-title":"J Mov Disord"},{"key":"935_CR12","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s13311-020-00960-0","volume":"17","author":"PA Vaswani","year":"2020","unstructured":"Vaswani PA, Tropea TF, Dahodwala N. Overcoming barriers to Parkinson disease trial participation: increasing diversity and novel designs for recruitment and retention. Neurotherapeutics. 2020;17:1724\u201335.","journal-title":"Neurotherapeutics"},{"key":"935_CR13","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3233\/JPD-240272","volume":"14","author":"K McFarthing","year":"2024","unstructured":"McFarthing K, Buff S, Rafaloff G, et al. Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2024 update. J Parkinsons Dis. 2024;14:899\u2013912.","journal-title":"J Parkinsons Dis"},{"key":"935_CR14","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.3233\/JPD-230235","volume":"14","author":"S Mathur","year":"2024","unstructured":"Mathur S, Mathur S. Patient empowerment for those living with Parkinson\u2019s disease. J Parkinsons Dis. 2024;14:S173\u201380.","journal-title":"J Parkinsons Dis"},{"key":"935_CR15","unstructured":"NHS England. Health literacy \u2018how to\u2019 guide. https:\/\/library.nhs.uk\/wp-content\/uploads\/sites\/4\/2020\/08\/Health-literacy-how-to-guide.pdf. Accessed March 2026."},{"key":"935_CR16","doi-asserted-by":"publisher","first-page":"378\u201382","DOI":"10.4140\/TCP.n.2008.378","volume":"23","author":"C Agness","year":"2008","unstructured":"Agness C, Murrell E, Nkansah N, Martin CM. Poor health literacy as a barrier to patient care. Consult Pharm. 2008;23:378\u201382, 285\u20136.","journal-title":"Consult Pharm"},{"key":"935_CR17","unstructured":"Institute for Safe Medication Practices (ISMP). ISMP Medication Safety Alert! Patients with low health literacy make more errors interpreting instructions and warnings. Acute Care. 2023;28:1\u20133."},{"key":"935_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08527-9","volume":"22","author":"R Shahid","year":"2022","unstructured":"Shahid R, Shoker M, Chu LM, Frehlick R, Ward H, Pahwa P. Impact of low health literacy on patients\u2019 health outcomes: a multicenter cohort study. BMC Health Serv Res. 2022;22:1148.","journal-title":"BMC Health Serv Res"},{"key":"935_CR19","doi-asserted-by":"crossref","unstructured":"Udow SJ, Hobson DE, Kleiner G, et al. Educational needs and considerations for a visual educational tool to discuss Parkinson\u2019s disease. Mov Disord Clin Pract. 2018;5:66\u201374.","DOI":"10.1002\/mdc3.12563"},{"key":"935_CR20","unstructured":"The Ohio State University. Suitability Assessment of Materials (SAM). https:\/\/ogg.osu.edu\/media\/documents\/health_lit\/HOSAM2006.pdf. Accessed March 2026."},{"key":"935_CR21","doi-asserted-by":"crossref","unstructured":"Rooney MK, Santiago G, Perni S, et al. Readability of patient education materials from high-impact medical journals: a 20-year analysis. J Patient Exp. 2021;8:2374373521998847.","DOI":"10.1177\/2374373521998847"},{"key":"935_CR22","doi-asserted-by":"crossref","unstructured":"Morel T, Cleanthous S, Andrejack J, et al. Patient experience in early-stage Parkinson\u2019s disease: using a mixed methods analysis to identify which concepts are cardinal for clinical trial outcome assessment. Neurol Ther. 2022;11:1319\u201340.","DOI":"10.1007\/s40120-022-00375-3"},{"key":"935_CR23","doi-asserted-by":"publisher","first-page":"6949","DOI":"10.1080\/09638288.2021.1981467","volume":"44","author":"G Wieringa","year":"2022","unstructured":"Wieringa G, Dale M, Eccles FJR. Adjusting to living with Parkinson\u2019s disease; a meta-ethnography of qualitative research. Disabil Rehabil. 2022;44:6949\u201368.","journal-title":"Disabil Rehabil"},{"key":"935_CR24","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1111\/jgs.17774","volume":"70","author":"ZS Tan","year":"2022","unstructured":"Tan ZS. The dawn of disease modification for Alzheimer\u2019s disease: hope and peril. J Am Geriatr Soc. 2022;70:1661\u20133.","journal-title":"J Am Geriatr Soc"},{"key":"935_CR25","doi-asserted-by":"publisher","DOI":"10.2196\/22122","volume":"24","author":"L Mart\u00ednez Silvagnoli","year":"2022","unstructured":"Mart\u00ednez Silvagnoli L, Shepherd C, Pritchett J, Gardner J. Optimizing readability and format of plain language summaries for medical research articles: cross-sectional survey study. J Med Internet Res. 2022;24:e22122.","journal-title":"J Med Internet Res"},{"key":"935_CR26","doi-asserted-by":"crossref","unstructured":"Derollez C, Carriere N, Kyheng M, et al. Factors that predict a change in quality of life among Parkinson\u2019s disease patients participating in a patient education program. Rev Neurol (Paris). 2021;177:1151\u20139.","DOI":"10.1016\/j.neurol.2021.01.020"},{"key":"935_CR27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/JNN.0000000000000521","volume":"52","author":"H Hakim","year":"2020","unstructured":"Hakim H, Newland P, Oliver BJ. Initial user testing of decision aids for multiple sclerosis disease-modifying therapies. J Neurosci Nurs. 2020;52:160\u20135.","journal-title":"J Neurosci Nurs"},{"key":"935_CR28","doi-asserted-by":"crossref","unstructured":"Ailabouni NJ, Hanjani LS, Weir KR, et al. Empowerment to have a conversation with healthcare professionals: co-designing the PRIME (PReparing people living with dementia and carers to Initiate conversations about their MEdicines) tool. J Alzheimers Dis. 2026;109:1439\u201357.","DOI":"10.1177\/13872877251406907"},{"key":"935_CR29","doi-asserted-by":"crossref","unstructured":"Dietzel N, Graessel E, K\u00fcrten L, et al. The Dementia Assessment of Service Needs (DEMAND): development and validation of a standardized needs assessment instrument. J Alzheimers Dis. 2022;89:1051\u201361.","DOI":"10.3233\/JAD-220363"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00935-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00935-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00935-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:26Z","timestamp":1784819486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00935-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["935"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00935-x","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Soania Mathur has nothing to disclose. Harold de Wit has nothing to disclose. Becky Jones is an employee of Parkinson\u2019s UK. Evelyn Stevens is an employee of the Parkinson\u2019s Foundation. Angels Costa is an employee of Novartis. Alexander Klein and Kate Trenam are employees and shareholders of UCB.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Based on the European Pharmaceutical Market Research Association Code of Conduct (Sections\u00a01.1 and 1.2), this study can be defined as market research. Therefore, neither Ethics Committee nor Independent Review Board approval (Section 1.3) was required. None of the participants received any honoraria for their time or contributions to the research, and consent to publish the findings was received by the patient advocacy groups on behalf of the participants.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}